• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Epidemiologic and clinical characteristics of heart transplant recipients during the 2019 coronavirus outbreak in Wuhan, China: A descriptive survey report.2019 年冠状病毒病疫情期间武汉心脏移植受者的流行病学和临床特征:描述性调查研究报告。
J Heart Lung Transplant. 2020 May;39(5):412-417. doi: 10.1016/j.healun.2020.03.008. Epub 2020 Mar 25.
2
Risk estimation of the SARS-CoV-2 acute respiratory disease outbreak outside China.中国境外新型冠状病毒急性呼吸道疾病爆发的风险评估
Theor Biol Med Model. 2020 Jun 5;17(1):9. doi: 10.1186/s12976-020-00127-6.
3
The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China.致命的冠状病毒:2003 年 SARS 大流行和 2020 年中国新型冠状病毒疫情。
J Autoimmun. 2020 May;109:102434. doi: 10.1016/j.jaut.2020.102434. Epub 2020 Mar 3.
4
Coronavirus Disease 2019 Pneumonia in Immunosuppressed Renal Transplant Recipients: A Summary of 10 Confirmed Cases in Wuhan, China.新型冠状病毒肺炎合并免疫抑制的肾移植受者肺炎:中国武汉 10 例确诊病例总结
Eur Urol. 2020 Jun;77(6):748-754. doi: 10.1016/j.eururo.2020.03.039. Epub 2020 Apr 18.
5
Kidney allograft recipients, immunosuppression, and coronavirus disease-2019: a report of consecutive cases from a New York City transplant center.肾移植受者、免疫抑制和 2019 年冠状病毒病:来自纽约市移植中心的连续病例报告。
Nephrol Dial Transplant. 2020 Jul 1;35(7):1250-1261. doi: 10.1093/ndt/gfaa154.
6
Preparation for Quarantine on the Cruise Ship Diamond Princess in Japan due to COVID-19.因 COVID-19 对停靠在日本的“钻石公主”号游轮进行隔离的准备工作。
JMIR Public Health Surveill. 2020 May 11;6(2):e18821. doi: 10.2196/18821.
7
The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment.新型冠状病毒(SARS-CoV-2)爆发的前 75 天:最新进展、预防和治疗。
Int J Environ Res Public Health. 2020 Mar 30;17(7):2323. doi: 10.3390/ijerph17072323.
8
The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status.2019 冠状病毒病(COVID-19)疫情的起源、传播和临床治疗——现状更新。
Mil Med Res. 2020 Mar 13;7(1):11. doi: 10.1186/s40779-020-00240-0.
9
Fighting against the common enemy of COVID-19: a practice of building a community with a shared future for mankind.抗击新冠肺炎这一共同敌人:构建人类命运共同体的实践。
Infect Dis Poverty. 2020 Apr 7;9(1):34. doi: 10.1186/s40249-020-00650-1.
10
Interaction of SARS-CoV-2 and Other Coronavirus With ACE (Angiotensin-Converting Enzyme)-2 as Their Main Receptor: Therapeutic Implications.SARS-CoV-2 与其他冠状病毒与 ACE(血管紧张素转换酶)-2 作为其主要受体的相互作用:治疗意义。
Hypertension. 2020 Nov;76(5):1339-1349. doi: 10.1161/HYPERTENSIONAHA.120.15256. Epub 2020 Aug 27.

引用本文的文献

1
COVID-19 Pandemic and Cardiovascular Disease.2019冠状病毒病大流行与心血管疾病
US Cardiol. 2020 Mar 25;14:e01. doi: 10.15420/usc.2020.14. eCollection 2020.
2
2023 Chinese expert consensus on the impact of COVID-19 on the management of cardiovascular diseases.《2023年新型冠状病毒肺炎对心血管疾病管理影响的中国专家共识》
Cardiol Plus. 2023 Apr-Jun;8(2):82-102. doi: 10.1097/CP9.0000000000000043. Epub 2023 Jul 20.
3
How the Heart Was Involved in COVID-19 during the First Pandemic Phase: A Review.在大流行第一阶段新冠病毒病中心脏是如何受累的:一项综述
Epidemiologia (Basel). 2021 Mar 22;2(1):124-139. doi: 10.3390/epidemiologia2010011.
4
ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up.ESC 指导意见:COVID-19 大流行期间心血管疾病的诊断和管理:第 2 部分——治疗途径、治疗和随访。
Cardiovasc Res. 2022 Jun 22;118(7):1618-1666. doi: 10.1093/cvr/cvab343.
5
ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up.ESC 指导意见:COVID-19 大流行期间心血管疾病的诊断和管理:第 2 部分——治疗途径、治疗和随访。
Eur Heart J. 2022 Mar 14;43(11):1059-1103. doi: 10.1093/eurheartj/ehab697.
6
Potential Effects of Coronaviruses on the Liver: An Update.冠状病毒对肝脏的潜在影响:最新进展
Front Med (Lausanne). 2021 Sep 27;8:651658. doi: 10.3389/fmed.2021.651658. eCollection 2021.
7
COVID-19 Risk Mapping with Considering Socio-Economic Criteria Using Machine Learning Algorithms.利用机器学习算法考虑社会经济标准的 COVID-19 风险测绘。
Int J Environ Res Public Health. 2021 Sep 14;18(18):9657. doi: 10.3390/ijerph18189657.
8
Management of post cardiac transplantation immunosuppression and COVID-19: A case report.心脏移植术后免疫抑制与新型冠状病毒肺炎的管理:一例报告
Ann Med Surg (Lond). 2021 Nov;71:102875. doi: 10.1016/j.amsu.2021.102875. Epub 2021 Sep 21.
9
Trends in Heart and Lung Transplantation in the United States Across the COVID-19 Pandemic.美国在新冠疫情期间心肺移植的趋势
Transplant Direct. 2021 Sep 7;7(10):e759. doi: 10.1097/TXD.0000000000001224. eCollection 2021 Oct.
10
Impact of COVID-19 infection on the cardiovascular system: An evidence-based analysis of risk factors and outcomes.COVID-19 感染对心血管系统的影响:基于证据的危险因素和结局分析。
Best Pract Res Clin Anaesthesiol. 2021 Oct;35(3):437-448. doi: 10.1016/j.bpa.2021.02.003. Epub 2021 Mar 1.

本文引用的文献

1
Renin-angiotensin system in human coronavirus pathogenesis.人类冠状病毒发病机制中的肾素-血管紧张素系统。
Future Virol. 2010 Mar;5(2):145-161. doi: 10.2217/fvl.10.4. Epub 2010 Mar 1.
2
High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa.2019-nCoV 对口腔黏膜上皮细胞 ACE2 受体的高表达。
Int J Oral Sci. 2020 Feb 24;12(1):8. doi: 10.1038/s41368-020-0074-x.
3
Pathological findings of COVID-19 associated with acute respiratory distress syndrome.与急性呼吸窘迫综合征相关的新型冠状病毒肺炎的病理表现
Lancet Respir Med. 2020 Apr;8(4):420-422. doi: 10.1016/S2213-2600(20)30076-X. Epub 2020 Feb 18.
4
Reducing mortality from 2019-nCoV: host-directed therapies should be an option.降低2019新型冠状病毒所致死亡率:宿主导向疗法应成为一种选择。
Lancet. 2020 Feb 22;395(10224):e35-e36. doi: 10.1016/S0140-6736(20)30305-6. Epub 2020 Feb 5.
5
Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.《武汉 2019 年新型冠状病毒感染的肺炎 138 例住院患者临床特征分析》
JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585.
6
A pneumonia outbreak associated with a new coronavirus of probable bat origin.一种新型冠状病毒引发的肺炎疫情,该病毒可能来源于蝙蝠。
Nature. 2020 Mar;579(7798):270-273. doi: 10.1038/s41586-020-2012-7. Epub 2020 Feb 3.
7
Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission.新型冠状病毒在武汉持续爆发中的进化及其刺突蛋白对人类传播风险的建模。
Sci China Life Sci. 2020 Mar;63(3):457-460. doi: 10.1007/s11427-020-1637-5. Epub 2020 Jan 21.
8
Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.中国武汉 99 例 2019 年新型冠状病毒肺炎患者的流行病学和临床特征:描述性研究。
Lancet. 2020 Feb 15;395(10223):507-513. doi: 10.1016/S0140-6736(20)30211-7. Epub 2020 Jan 30.
9
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.中国武汉地区 2019 年新型冠状病毒感染患者的临床特征。
Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
10
A Novel Coronavirus from Patients with Pneumonia in China, 2019.2019 年中国肺炎患者中的一种新型冠状病毒。
N Engl J Med. 2020 Feb 20;382(8):727-733. doi: 10.1056/NEJMoa2001017. Epub 2020 Jan 24.

2019 年冠状病毒病疫情期间武汉心脏移植受者的流行病学和临床特征:描述性调查研究报告。

Epidemiologic and clinical characteristics of heart transplant recipients during the 2019 coronavirus outbreak in Wuhan, China: A descriptive survey report.

机构信息

Department of Cardiovascular Surgery, Renmin Hospital of Wuhan University, Wuhan, China.

Department of Cardiovascular Surgery, Renmin Hospital of Wuhan University, Wuhan, China.

出版信息

J Heart Lung Transplant. 2020 May;39(5):412-417. doi: 10.1016/j.healun.2020.03.008. Epub 2020 Mar 25.

DOI:10.1016/j.healun.2020.03.008
PMID:32362392
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7102567/
Abstract

BACKGROUND

The epidemiologic and clinical characteristics of heart transplant (HTx) recipients during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic remains unclear. We studied the characteristics of HTx recipients from December 20, 2019, to February 25, 2020, in an effort to understand their risk and outcomes.

METHODS

All accessible HTx recipients were included in this single-center retrospective study. We collected information on the recipients using a web-based questionnaire as well as the hospital database.

RESULTS

We followed 87 HTx recipients (72.4% were men, and the average age was 51 years). A total of 79 recipients resided in Hubei, and 57 recipients had a Wuhan-related history of travel or contact. Most took precautionary measures while in contact with suspicious crowds, and 96.6% of the families and communities undertook prevention and quarantine procedures. Four upper airway infections were reported, and 3 of them tested negative for SARS-CoV-2 (the fourth recovered and was not tested). All cases were mild and successfully recovered after proper treatment. Laboratory results of 47 HTx cases within the last 2 months were extracted. Of these, 21.3% of recipients had pre-existing lymphopenia, and 87.2% of recipients had a therapeutic concentration of tacrolimus (5-12 ng/ml). Liver and kidney insufficiency was seen in 5 and 6 recipients, respectively.

CONCLUSION

HTx recipients who practiced appropriate prevention measures had a low rate of infection with SARS-CoV-2 and transition to the associated disease COVID-19. These early data will require confirmation as the pandemic establishes around the world.

摘要

背景

严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)流行期间,心脏移植(HTx)受者的流行病学和临床特征尚不清楚。我们研究了 2019 年 12 月 20 日至 2020 年 2 月 25 日期间 HTx 受者的特征,以了解他们的风险和结局。

方法

本单中心回顾性研究纳入了所有可获得的 HTx 受者。我们使用基于网络的问卷调查和医院数据库收集受者信息。

结果

我们随访了 87 例 HTx 受者(72.4%为男性,平均年龄为 51 岁)。共有 79 例受者居住在湖北,57 例受者有武汉相关旅行或接触史。大多数受者在接触可疑人群时采取了预防措施,96.6%的家庭和社区采取了预防和检疫措施。报告了 4 例上呼吸道感染,其中 3 例 SARS-CoV-2 检测结果为阴性(第 4 例已康复,未进行检测)。所有病例均为轻症,经适当治疗后均成功康复。提取了最近 2 个月内的 47 例 HTx 病例的实验室结果。其中,21.3%的受者存在预先存在的淋巴细胞减少症,87.2%的受者他克莫司(5-12ng/ml)治疗浓度。分别有 5 例和 6 例受者出现肝肾功能不全。

结论

采取适当预防措施的 HTx 受者 SARS-CoV-2 感染率较低,且向相关疾病 COVID-19 转化的比例较低。随着全球大流行的发展,这些早期数据需要进一步确认。